Nadja West Sells 3,000 Shares of Tempus AI (NASDAQ:TEM) Stock

Posted by Brenda Bartman on Sep 1st, 2026

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) Director Nadja West sold 3,000 shares of the stock in a transaction on Friday, August 28th. The shares were sold at an average price of $69.00, for a total value of $207,000.00. Following the transaction, the director directly owned 31,981 shares in the company, valued at $2,206,689. The trade was a 8.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Performance

Tempus AI stock traded down $0.78 during mid-day trading on Tuesday, reaching $62.27. 6,218,304 shares of the stock traded hands, compared to its average volume of 6,083,589. The stock has a market capitalization of $11.24 billion, a PE ratio of -43.24 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The business’s 50-day moving average is $54.93 and its 200-day moving average is $51.81. Tempus AI, Inc. has a 12-month low of $40.77 and a 12-month high of $104.32.

Tempus AI (NASDAQ:TEM – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. During the same quarter in the prior year, the firm earned ($0.22) EPS. The business’s revenue for the quarter was up 21.6% compared to the same quarter last year. As a group, sell-side analysts predict that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TEM has been the subject of several recent research reports. Wolfe Research assumed coverage on Tempus AI in a report on Tuesday, June 2nd. They set a “peer perform” rating for the company. HC Wainwright decreased their target price on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a research note on Monday, August 3rd. Lake Street Capital cut shares of Tempus AI to a “hold” rating in a research note on Monday, July 20th. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. Finally, Weiss Ratings lowered Tempus AI from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Ten analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Tempus AI presently has an average rating of “Hold” and an average price target of $67.23.

Read Our Latest Report on Tempus AI

Institutional Trading of Tempus AI

Several hedge funds have recently bought and sold shares of the stock. Pictet Asset Management Holding SA increased its stake in Tempus AI by 291.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock worth $2,948,000 after acquiring an additional 36,096 shares during the last quarter. Eagle Health Investments LP purchased a new position in shares of Tempus AI in the 1st quarter worth $11,588,000. Alethea Capital Management LLC purchased a new stake in shares of Tempus AI during the 4th quarter valued at about $1,863,000. Aristotle Atlantic Partners LLC purchased a new position in Tempus AI in the first quarter worth about $6,179,000. Finally, Vanguard Group Inc. raised its position in Tempus AI by 8.7% during the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after purchasing an additional 817,014 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

(Get Free Report)

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.